Loading market dashboard
Edwards Lifesciences Corporation
EWHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
On May 22, 2026, Edwards Lifesciences Corp (EW) shares rose 3.1% to a current price of $85.78. The stock has fluctuated between $72.30 and $87.89 over the past
On May 13, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown varied price performance recently. The stock has ex
Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript
On May 11, 2026, Edwards Lifesciences Corp (EW) shares fell 3.5%, bringing the current price to $77.17. The stock has experienced a 52-week range of $72.30 to $
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planni.
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospectiv.
During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox. In addition to Linde, Shopify and Amazon, we also added to Woodward and Spotify during the quarter. We ended our investment campaigns in Netflix, Snowflake and RELX during the quarter.
On April 29, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown mixed price performance recently. Over the past w
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences.
LENSAR (NASDAQ: LNSR - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Volatility and Risk LENSAR has a beta of 0.99,
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.
Edwards Lifesciences beats on Q1 earnings, matches revenue estimates, lifts 2026 outlook as TAVR and TMTT growth accelerates; shares rise on stronger guidance and margin expansion.
Edwards Lifesciences Corp (NYSE:EW) shares are up on Friday as the company reported strong first-quarter results, highlighting growth in its transcatheter mitral and tricuspid therapies.
Sales Growth: 12.7% year-over-year increase in Q1 2026.Total Sales: $1.65 billion in Q1 2026.TAVR Sales: $1.2 billion, 11% increase over the prior year.TMTT Sa
Edwards Lifesciences Corporation (EW) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Edwards Lifesciences beat Wall Street first-quarter estimates on Thursday, driven by robust demand for its artificial valves used in complex cardiac procedures, sending its shares up over 4% in extended trading.
Edwards Lifesciences stock advanced late Thursday on better-than-expected first-quarter sales and earnings.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to.
On April 23, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company currently trading at $81.53. The stock has shown some volatility
EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.
Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 27.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 109,749 shares of the medical research company's stock after buying an additional
Birch Hill Investment Advisors LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE: EW) by 1.8% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 743,680 shares of the medical research company's stock after selling 13,385
We are actively monitoring Meta Platforms' social and data privacy risks and believe the company has made progress on strengthening its policies and enforcement. We believe the market is underestimating the durability of Edwards' transcatheter aortic valve replacement franchise and the opportunity for its transcatheter mitral and tricuspid therapies. We exited our position in Workday to bring the portfolio's software exposure closer to market weight.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.
Edwards Lifesciences Corporation (NYSE: EW - Get Free Report) CFO Scott Ullem sold 13,000 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the
Edwards Lifesciences Corporation (NYSE: EW - Get Free Report) VP Donald Bobo, Jr. sold 22,680 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the transaction, the vice president owned 21,266 shares in the
Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as...
Tilray Inc (NASDAQ:TLRY) earned a repeat ‘Buy’ rating from Jefferies analysts after what it described as a solid third quarter earnings report, pointing to...
Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter...
The forex market now turns over $9.6 trillion every single day. That figure, confirmed by the Bank for International Settlements in its 2025 Triennial...
Boston Common Asset Management LLC boosted its holdings in Edwards Lifesciences Corporation (NYSE: EW) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 144,703 shares of the medical research company's stock after buying an additional 9,028 shares during the quarter.
NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025). The new TRISCEND II trial data presented today during.
Edwards Lifesciences (NYSE: EW - Get Free Report) and ERBA Diagnostics (OTCMKTS:ERBA - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations. Institutional and Insider Ownership 79.5% of Edwards Lifesciences
Brevan Howard Capital Management LP lowered its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 41.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,272 shares of the medical research company's stock after selling 33,100 shares during
Edwards Lifesciences delivered 11% revenue growth in 2025, driven by robust TAVR and accelerating TMTT businesses. Edwards Lifesciences guides for 8-10% sales growth and adjusted EPS of $2.90-$3.05 in 2026, with TMTT sales expected to rise 40%. Valuation has compressed to 26x forward earnings, supported by a strong net cash position and ongoing share repurchases.
Banco Bilbao Vizcaya Argentaria S.A. lifted its position in Edwards Lifesciences Corporation (NYSE: EW) by 9.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 218,749 shares of the medical research company's stock after acquiring an additional 18,498 shares
Banque Transatlantique SA trimmed its position in Edwards Lifesciences Corporation (NYSE: EW) by 32.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,434 shares of the medical research company's stock after selling 18,134 shares during the
EW shares jump 22.1% in a year as growth in TMTT and strong adoption of PASCAL, EVOQUE and SAPIEN technologies fuel momentum.
Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript
Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.
Shares of Edwards Lifesciences Corporation (NYSE: EW - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-seven brokerages that are presently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong
